Interstitial Lung Disease Trial, Recruiting (NCT06036719)

Interstitial Lung Disease Trial, Recruiting NCT06036719 Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06036719 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with a type of lung scarring disease (called idiopathic interstitial pneumonia or IIP), confirmed through medical tests, scans, or breathing tests
You have a progressive scarring lung disease (not IPF) where scans show at least 10% of your lungs are affected, your disease has been getting worse despite treatment over up to 24 months, and the worsening is not caused by a blood clot in the lungs, heart failure, or a lower respiratory tract infection — AND either your breathing capacity has dropped by at least 10%, OR at least two of the following apply: your breathing capacity dropped between 5–10%, your breathing symptoms have worsened, or your lung scarring has increased on a scan
You have been diagnosed with a lung disease linked to the condition Systemic Sclerosis (a type of autoimmune disease affecting connective tissue), confirmed using recognised medical criteria, with a disease severity score of 9 or more and at least 10% of your lungs affected on a detailed CT scan
You are a close blood relative (parent, child, or sibling) of a patient who carries a fault in one of several specific genes linked to how the body maintains its cells (including genes called TERT, TERC, RTEL1, TINF2, DKC1, or PARN, or similar genes that may be added in the future)

Who may not be able to join:

No exclusion criteria were listed in the information provided (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vincent Cottin, Pr, Centre National de Référence des maladies pulmonaires rares

Phone: (33) 4 27 85 77 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06036719

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

Trial contact: (33) 4 27 85 77 00

More information: https://clinicaltrials.gov/study/NCT06036719

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with a type of lung scarring disease (called idiopathic interstitial pneumonia or IIP), confirmed through medical tests, scans, or breathing tests
You have a progressive scarring lung disease (not IPF) where scans show at least 10% of your lungs are affected, your disease has been getting worse despite treatment over up to 24 months, and the worsening is not caused by a blood clot in the lungs, heart failure, or a lower respiratory tract infection — AND either your breathing capacity has dropped by at least 10%, OR at least two of the following apply: your breathing capacity dropped between 5–10%, your breathing symptoms have worsened, or your lung scarring has increased on a scan
You have been diagnosed with a lung disease linked to the condition Systemic Sclerosis (a type of autoimmune disease affecting connective tissue), confirmed using recognised medical criteria, with a disease severity score of 9 or more and at least 10% of your lungs affected on a detailed CT scan
You are a close blood relative (parent, child, or sibling) of a patient who carries a fault in one of several specific genes linked to how the body maintains its cells (including genes called TERT, TERC, RTEL1, TINF2, DKC1, or PARN, or similar genes that may be added in the future)

Who may not be able to join:

No exclusion criteria were listed in the information provided (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Registry

ClinicalTrials.gov

Start date

19 January 2022

Est. completion

19 March 2031

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Family history; Clinical parameters : respiratory examination; Collection of biological parameters; Chest scan; Chest radiographs; Pulmonary scintigraphy; Chest RMI; Echocardiography; Search for infectious agents; Bronchoscopy; Lung function tests: Arterial blood gas; Lung function tests: if available sleep gas exchange; Lung function tests: polysomnography; Lung tissue examination, if available Lung biopsy (surgical, transbronchial), Lung explant, if lung transplant; Assessment of digestive function; Assessment of cardiac function (cardiovascular ultrasound); Assessment of cardiac function (c...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov